Methods of treating chronic wounds with amniotic fluid having elevated levels of tissue inhibitors of matrix metalloproteinases
AssigneeLiventa Bioscience, Inc.
InventorJeffrey S. WHITE
Life of this patent
Estimating the term…
Abstract
Methods for treating chronic wounds with an amniotic fluid having a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) are described. The amniotic fluid can be obtained from a female donor during a period of gestation when the concentration of endogenous TIMPs are at or near their maximum level. The methods described herein are particularly useful for promoting wound healing in chronic wounds having elevated protease activity, such as increased amounts or specific activity of matrix metalloproteinases.
Claims20
A method of treating a chronic wound in a subject comprising applying a human amniotic fluid or a processed human amniotic fluid comprising a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) to the chronic wound, thereby treating the chronic wound.
A method of treating a chronic wound in a subject, wherein the chronic wound has elevated protease activity, the method comprising:
- (1) identifying a chronic wound as having elevated protease activity;
- and
- (2) applying a human amniotic fluid or a processed human amniotic fluid comprising a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases to the chronic wound identified as having elevated protease activity,
- thereby treating the chronic wound.
A wound dressing comprising a human amniotic fluid or a processed human amniotic fluid comprising a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs).
Dependencies are inferred from the claim text.